Increased Nitroxidative Stress Promotes Mitochondrial Dysfunction in Alcoholic and Nonalcoholic Fatty Liver Disease

Byoung-Joon Song, 1 Mohamed A. Abdelmegeed, 1 Lauren E. Henderson, 1 Seong-Ho Yoo, 1, 2 Jie Wan, 1 Vishnudutt Purohit, 3 James P. Hardwick, 4 and Kwan-Hoon Moon 1, 5

1 Section of Molecular Pharmacology and Toxicology, Laboratory of Membrane Biochemistry and Biophysics, National Institute on Alcohol Abuse and Alcoholism, 9000 Rockville Pike, Bethesda, MD 20892, USA
2 Department of Forensic Medicine, Seoul National University College of Medicine, Seoul 110, Republic of Korea
3 National Institute on Drug Abuse, Bethesda, MD 20892, USA
4 Department of Integrative Medical Sciences, Northeastern Ohio University College of Medicine, Rootstown, OH 44272, USA
5 Department of Molecular Pharmacology and Therapeutics, Loyola University Medical Center, Maywood, IL 60153, USA

Correspondence should be addressed to Byoung-Joon Song; bj.song@nih.gov

Received 9 January 2013; Accepted 27 February 2013

Academic Editor: Sumitra Miriyala

Copyright © 2013 Byoung-Joon Song et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Increased nitroxidative stress causes mitochondrial dysfunctions through oxidative modifications of mitochondrial DNA, lipids, and proteins. Persistent mitochondrial dysfunction sensitizes the target cells/organs to other pathological risk factors and thus ultimately contributes to the development of more severe disease states in alcoholic and nonalcoholic fatty liver disease. The incidences of nonalcoholic fatty liver disease continuously increase due to high prevalence of metabolic syndrome including hyperlipidemia, hypercholesterolemia, obesity, insulin resistance, and diabetes. Many mitochondrial proteins including the enzymes involved in fat oxidation and energy supply could be oxidatively modified (including S-nitrosylation/nitration) under increased nitroxidative stress and thus inactivated, leading to increased fat accumulation and ATP depletion. To demonstrate the underlying mechanism(s) of mitochondrial dysfunction, we employed a redox proteomics approach using biotin-N-maleimide (biotin-NM) as a sensitive biotin-switch probe to identify oxidized Cys residues of mitochondrial proteins in the experimental models of alcoholic and acute liver disease. The aims of this paper are to briefly describe the mechanisms, functional consequences, and detection methods of mitochondrial dysfunction. We also describe advantages and limitations of the Cys-targeted redox proteomics method with alternative approaches. Finally, we discuss various applications of this method in studying oxidatively modified mitochondrial proteins in extrahepatic tissues or different subcellular organelles and translational research.

1. Introduction

Mitochondria are responsible for the production of energy in the form of ATP which is used by every cell for its survival and function. In addition, mitochondria play a critical role in fatty acid oxidation, antioxidant defense, apoptosis, intermediary metabolism (including ammonia, urea, heme, steroid, pyrimidine, one carbon transfer, and glutamine metabolism), and so forth, [1–3]. The mitochondrial fat oxidation pathway is very important in providing alternative energy (e.g., ketone bodies) when glucose is supplied in limited amounts or not utilized for maximal energy production through the mitochondrial tricarboxylic acid cycle under various disease states [1]. It is known that heavy and chronic alcohol (ethanol) intake causes alcoholic fatty liver, steatohepatitis (inflammation), fibrosis, cirrhosis, and carcinogenesis in humans and experimental animal models [4, 5]. Because of the high solubility of alcohol, it is distributed in most tissues; therefore, excessive alcohol intake (e.g., binge or chronic heavy alcohol drinking) can damage virtually all tissues including liver, heart, brain, lung, pancreas, and testes [6–8]. Continuous consumption of calorie-enriched high-fat diets or administration of a choline-deficient diet in experimental animals can also cause
significant fatty liver disease (i.e., nonalcoholic fatty liver disease) [9, 10], which are clinically similar to those of the aforementioned alcoholic fatty liver disease. In addition, acute and chronic infection from hepatitis viruses can increase oxidative stress and cause various liver diseases including fibrosis and cirrhosis depending on the degree of host-viral interactions [11]. Certain drugs such as the antibreast cancer agent tamoxifen and antiretroviral drugs including AZT (zidovudine) can promote fatty liver disease ([12], and references herein). Likewise, abused substances such as marijuana (cannabinoids), nicotine (a major component of tobacco smoke), and 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) can lead to hepatic steatosis and inflammation (steatohepatitis) [13–15] as well as tissue injury in extrahepatic organs including brain and heart [16–19].

Regardless of the etiological factors, both alcoholic and nonalcoholic fatty liver diseases can result from impaired mitochondrial functions (i.e., mitochondrial dysfunction) with suppressed β-oxidation of fatty acids [2, 12, 20]. Furthermore, some exogenous agents (e.g., alcohol or high-fat diet) alone or in combination with other gene-related comorbidity risk factors can damage the liver in a synergistic/additive manner to rapidly promote or worsen the preexisting conditions, as observed in rats [21]. It is also known that other extrahepatic tissues can be negatively affected or damaged by the combination of environmental factors (e.g., excessive amounts of alcohol consumption, smoking, drugs, and abused substances) and genetic factors (e.g., variations in disease susceptible genes such as a dominant negative mutation of mitochondrial aldehyde dehydrogenase (ALDH2) gene, frequently found in many East Asians [22–25], diabetes, obesity, and neurodegenerative diseases) (Figure 1). In fact, mitochondrial dysfunction could serve as a major contributor in many disease states such as alcohol- or drug-mediated tissue injury, aging, cancer, diabetes, and various neurodegenerative diseases [20, 26–31], even though the etiological factor for each disease state is different. Despite the well-established role of mitochondrial dysfunction in many disease states, it is poorly understood how mitochondrial dysfunction occurs in these pathological conditions. In this paper, we briefly describe the role of nitrooxidative stress in promoting mitochondrial dysfunction and its pathophysiological consequences. We also describe the detection of oxidatively modified mitochondrial proteins in experimental models of alcoholic and nonalcoholic fatty liver disease with redox-based proteomics approaches. Finally, we discuss potential limitations and applications of redox proteomics approaches in studying oxidatively modified proteins in different subcellular fractions in various tissues as well as future translational research.

2. Role of Oxidative Stress in Promoting Mitochondrial Dysfunction

Under normal conditions, approximately 1%-2% of oxygen leaks out as reactive oxygen species (ROS) from the mitochondrial electron transport chain (ETC) [32]. These amounts of ROS, adequately handled by the cellular defense systems under normal conditions, can regulate various cellular signaling pathways, as recently discussed [33]. However, under pathological conditions or after exposure to certain toxic agents including large quantities of alcohol, abused substances, or other therapeutic drugs [17–20, 30], greater amounts of ROS are leaked from the mitochondrial ETC, possibly at the sites of Complex I (NADH ubiquinone oxidoreductase) and Complex III (ubiquinone cytochrome c oxidoreductase), as shown in alcohol-exposed hepatocytes [34]. Ironically, mitochondria, a major source of cellular ROS, become a main target of oxidative damage because of the relatively low levels of antioxidants, such as reduced glutathione (GSH), in mitochondria compared to cytosol [35]. Consistent with a notion of ROS-mediated damage, mitochondria from tissues in animal disease models and/or human diseases show abnormal and irregular shapes and decreased functions [36, 37].

Besides the ROS generation from the mitochondrial ETC, other cellular enzymes are also known to produce ROS and reactive nitrogen species (RNS) including nitric oxide (NO). These enzymes include NADPH oxidase and myeloperoxidase in phagocytic immune cells, ethanol-inducible cytochrome P450 2E1 (CYP2E1) and CYP4A isozymes in endoplasmic reticulum (ER), cytosolic xanthine oxidase, and nitric oxide synthase isozymes including the inducible form (iNOS) in activated Kupffer cells and/or recruited neutrophils [38–45]. Many of these prooxidant enzymes are induced or activated after exposure to potentially toxic agents such as alcohol, MDMA, and high-fat diets. Elevated ROS leaked from the mitochondrial ETC and produced by these enzymes lead to increased production of a potently toxic peroxynitrite (ONOO−) in the presence of NO. Peroxynitrite can covalently modify various proteins through nitration of Tyr residues [46, 47] and S-nitrosylation of Cys residues [48]. In fact, elevated ROS/RNS under pathological conditions suppress the activities of various antioxidant enzymes including mitochondrial superoxide dismutase (SOD2), catalase, glutathione peroxidase, and glutathione reductase while they can also decrease the levels of cellular antioxidants such as GSH and vitamins, causing increased nitrooxidative stress.

Under the conditions of elevated nitrooxidative stress, mitochondrial DNA, proteins, and lipids become covalently modified by oxidation, nitrosation, and/or nitration. Increased nitrosative stress can lead to various reactions, including N−, O−, and S-nitrosations, that modify structure of various proteins, as reviewed [49–52]. Nitrate stress represents a condition where excessive ROS reacts with NO to produce potently toxic peroxynitrite, which can nitrate Tyr residues of various proteins to produce 3-nitroTyr, frequently used as a stable marker for nitrate stress [48–52]. These types of modifications of cellular macromolecules likely contribute to alteration of their normal functions [53–55]. Deletion and/or mutation through oxidative modifications of mitochondrial DNA are particularly important, since they encode 13 polypeptides, all of which are subunits of the 4 mitochondrial ETC proteins (i.e., Complexes I, III, IV, and V) [30, 31]. Mitochondrial DNA and proteins are more susceptible to oxidative/nitrosative damage due to the absence of protective antioxidant protein catalase, histones,
and 4-HNE, and Sirt3, NAD+, involved in the metabolism of reactive acetaldehyde activities of many mitochondrial proteins such as ALDH2 dialdehyde (MDA). These lipid peroxides can suppress the peroxides such as 4-hydroxynonenal (4-HNE) and malonaldehyde-exposed rats [59].

Proteins, contributing to greater ROS production, as shown to reduced expression and function of mitochondrial ETC and/or deletion of mitochondrial DNA [57, 58] may lead to deficiency of GSH in mitochondria ([35], and references herein). One report suggested that the rate of mutation in mitochondrial DNA is 10-fold higher than that in the nuclear DNA [29]. In addition, the level of mitochondrial GSH is relatively low compared to that in cytosol because it has to be imported into mitochondria through the specific GSH transporter protein due to the absence of its synthesis in mitochondria. Furthermore, chronic alcohol exposure impairs the GSH transporter protein, leading to a selective deficiency of GSH in mitochondria ([35], and references herein). It is thus reasonable to assume that oxidative damage and/or deletion of mitochondrial DNA [57, 58] may lead to reduced expression and function of mitochondrial ETC proteins, contributing to greater ROS production, as shown in alcohol-exposed rats [59].

Oxidation of lipids also produces cytotoxic lipid peroxides such as 4-hydroxynonenal (4-HNE) and malondialdehyde (MDA). These lipid peroxides can suppress the activities of many mitochondrial proteins such as ALDH2 [60], involved in the metabolism of reactive acetaldehyde and 4-HNE, and Sirt3, NAD+-dependent deacetylase [61], through covalent modifications (mostly via adduct formation with many amino acid residues including Cys, His, and Lys) [54, 55]. These lipid peroxides can alter the cell membrane functions and promote fibrosis through activation of stellate cells with elevated production of collagen and proinflammatory cytokines/chemokines that lead to recruitment of neutrophils and activation of macrophage Kupffer cells. All these events contribute to profound mitochondrial dysfunction with increased fat accumulation and tissue injury in liver and various extrahepatic organs [4, 5, 28, 29].

Numerous investigators have reported the mechanisms and consequences of increased levels of oxidized mitochondrial DNA and lipid peroxides in various human disease states as well as experimental models for human disease [12, 53, 57, 62, 63]. Compared with the numerous reports about oxidative modifications of (mitochondrial) DNA and lipids, a much smaller number of reports systematically dealt with the oxidatively modified (mitochondrial) proteins under increased nitroxidative stress associated with many disease states. We believe that part of the reason for the relatively fewer reports on protein oxidation, nitrosation, and nitration might be due to the requirement for specific reagents, the lack of suitable methods to systematically identify and purify oxidatively modified proteins, and the relatively late development of highly sensitive mass spectral instruments. Because of the delayed development of specific methods to systematically study oxidatively modified proteins, the following questions have been poorly answered: (1) do we have a suitable method to systematically identify the oxidatively modified proteins and study the causes of mitochondrial dysfunction compared to global analysis of the changes in mitochondrial proteins? (2) what are the sources of ROS/RNS in enhancing oxidative protein modifications (including oxidation and nitration)? (3) which (mitochondrial) proteins are oxidatively modified? (4) are their activities/functions altered following oxidative modifications? (5) what are the functional implications of oxidized proteins in mitochondrial dysfunction and certain disease states such as various models of fatty liver disease? and (6) can the oxidative protein modifications and subsequent mitochondrial dysfunction be prevented with a potential therapeutic agent? and (7) how do current treatment modalities of fatty liver disease impact the function and oxidation of mitochondria proteins?

3. Consequences of Mitochondrial Dysfunction

Although both genetic and environmental factors synergistically promote mitochondrial dysfunction in various pathophysiological conditions, increased nitroxidative stress represents one important common factor (Figure 1). Despite
the well-established pathological role of elevated nitroxi-
dative stress, it has been poorly understood which mitochon-
drial proteins are oxidatively modified and whether their
functional alterations cause mitochondrial dysfunction prior
to full-blown tissue damage determined by histological and
biochemical assessments. Therefore, we hypothesized that
mitochondrial dysfunction is mediated by covalent modific-
ations (e.g., oxidation, nitrosation, nitration, phosphorylation,
acetylation, etc.) of various mitochondrial proteins, leading
to their inactivation or loss of their biological functions.
In case of mitochondrial dysfunction, we expect to observe
increased levels of energy depletion, lipid peroxidation, and
fat accumulation possibly due to suppressed activities of the
enzymes involved in ATP synthesis, ALDH2-mediated
metabolism, and fatty acid β-oxidation, respectively. In this
paper, we briefly describe the functional changes of oxida-
tively modified ATP synthase, ALDH2, and 3-ketoacyl-CoA
thiolase (thiolase) as examples.

Cederbaum et al. [64] and Chen et al. [65, 66] reported
that alcohol administration directly or indirectly suppressed
the activities of mitochondrial Complex enzymes through
increased oxidative stress. It is also likely that decreased
amounts of Complex I (NADH ubiquinone oxidoreductase),
and Complex IV (cytochrome c oxidase) observed in alcohol-
exposed rats [59] could have contributed to suppression of
their catalytic activities. Inhibition of these Complex activi-
ties could cause more ROS leakage from the mitochondrial
ETC, as observed in alcohol-exposed hepatocytes [34]. In
addition, ROS can be produced at the site of mitochondrial
Complex II (succinate dehydrogenase) [33].

By performing redox proteomics analysis, we sought to
identify oxidatively modified mitochondrial Complex proteins
in rat livers exposed to chronic or binge alcohol
compared to control rats [67]. Oxidation of many mito-
ochondrial proteins including Complexes I, III, and V protein
subunits was detected. Activity measurement showed that
ATP synthase (Complex V) was significantly inhibited in
alcohol-exposed rats possibly through oxidative modific-
ations (including nitration) of the enzyme [67]. Immunoblot
analysis with the anti-3-nitroTyr antibody verified the pres-
ence of a 3-nitroTyr-reactive band in the immunoprecipitated
ATP synthase protein only from alcohol-exposed livers,
suggesting its nitration. Mass spectral analysis confirmed the
nitration of Tyr residues in the catalytic β subunit, which
does not have a Cys residue but must have been copurified
with the Cys-containing α subunit of ATP synthase [67].
Nitration of the catalytic subunit of ATP synthase could have
contributed to its inactivation. The markedly suppressed ATP
synthase likely resulted in significantly decreased ATP levels,
as observed in many pathological conditions [68, 69].

Systematic redox proteomics analysis of oxidatively mod-
ified mitochondrial proteins in experimental models of acute
liver disease caused by alcohol, MDMA, or hepatic I/R
injury revealed the detection of all 4 enzymes (medium-
chain fatty acyl-CoA dehydrogenase, enoyl-CoA hydratase,
3-hydroxyacyl-CoA dehydrogenase, and thiolase), involved
in the mitochondrial β-oxidation of fatty acids [15, 67, 70].
Activity measurement of thiolase, the last enzyme in the
mitochondrial β-oxidation pathway of fatty acids, showed
inhibition of this enzyme in the animal models of alcoholic
fatty liver disease, possibly through oxidative modification
of the active site Cys residues (Cys^{32} and Cys^{382}) of thiol-
ase [67]. It is likely that the active site Cys residues
may undergo oxidation including S-nitrosylation as well as
formation of adducts with 4-HNE or MDA, since their
levels can be increased through lipid peroxidation under
oxidative stress. Because of the oxidative modifications of
3 other enzymes in the β-oxidation pathway, as mentioned
above, we expect that their activities could be altered in
alcohol-exposed rats. In addition, it is likely that the activity
of the NADPH-dependent 3-hydroxyacyl-CoA dehydrogenase
could be compromised due to significant changes in the
NAD^{+}/NADH levels following alcohol intake [4, 39]. At
any rate, oxidative modifications and subsequent inhibition of at
least one of the mitochondrial β-oxidation pathway enzymes
were likely due to hepatic inflammation and fat accumulation,
as assessed by biochemical measurements of triglycerides as
well as histological evaluations [67].

From the redox proteomics analysis, we also identified a
few oxidatively modified mitochondrial ALDH isozymes in
the mitochondria from alcohol-exposed rats [67]. The
ALDH gene family [71, 72] represents a large number of
NADPH-dependent dehydrogenases (defensive enzymes)
[73–75] involved in the cellular metabolism of reactive and
cytotoxic aldehyde carbonyl compounds such as acetalde-
hyde, MDA, 4-HNE, and other lipid aldehydes that are
produced during the lipid peroxidation process [54, 76].
The ALDH isozymes including mitochondrial ALDH2 are
known to be inactivated by genetic/environmental factors
[22–25, 71, 72, 77–79] and in many disease states [80–83].
Many isozymes of the ALDH gene family members includ-
ing retinal aldehyde dehydrogenase (ALDH1A1/2/3) and 10-
formyltetrahydrofolate dehydrogenase (ALDH1L1) contain
the highly conserved active site Cys residue [84]. Oxidative
modifications of the active site and other critical Cys residues
of a cytosolic high-Km ALDH1A1 and mitochondrial low-Km
ALDH2 (Km for acetaldehyde ≤ 0.2 μM) [75], an important
enzyme in the metabolism of toxic acetaldehyde produced
during ethanol oxidation, contribute to inhibition of their
activities [67, 84]. Under our experimental conditions, we
did not observe any significant changes in the ALDH1A1 or
ALDH2 protein content, strongly suggesting that inhibition
of these ALDH enzymes could be due to covalent modifi-
cations of critical Cys residues by S-nitrosylation and other
oxidative modifications, as discussed [85, 86]. Our results are
consistent with those of Venkatraman et al. who reported
inhibition of ALDH2 activity without change in its content
in alcohol-exposed rats, although the suppressed ALDH2
activity was not restored after incubation with 0.3 mM β-
mercaptoethanol, suggesting an irreversible ALDH2 inacti-
vation in their model [87]. Although we have not measured
the specific activities of other mitochondrial ALDH isozymes
such as ALDH5A1 (NAD^{+}-dependent succinic semial-
dehyde dehydrogenase involved in the catabolism of the neu-
rotransmitter gamma-aminobutyric acid), ALDH6A1 (meth-
ylmalonate semialdehyde dehydrogenase), and ALDH7A1
(α-aminoacidic semialdehyde dehydrogenase) [71, 88], their
activities are likely suppressed due to the highly conserved
active site Cys residue by a similar mechanism, as recently demonstrated with mitochondrial ALDH2 [67, 70, 85] and cytosolic ALDH1A1 [84]. Because of the inactivation of ALDH1A1, ALDH2, and other ALDH isozymes through covalent modifications such as S-nitrosylation [67, 85], phosphorylation [89], and other modifications [86] including adduct formations with MDA or 4-HNE [60, 90] or reactive drug metabolites [78, 79], we expect increased levels of highly reactive and cytotoxic carbonyl compounds including acetaldehyde, 4-HNE, and MDA.

In addition to ALDH isozymes, many other mitochondrial proteins were oxidatively modified and inactivated in alcohol-exposed rat livers [67] (Figure 2). We also observed similar patterns of oxidatively modified mitochondrial proteins in the animal models of acute liver disease from hepatic I/R injury [70] or MDMA exposure [14, 91], or during fasting-related oxidative stress [92]. We expect that similar patterns of oxidative modifications of many mitochondrial proteins would be identified in experimental models of nonalcoholic fatty liver disease caused by high fat diets [76] or methionine/choline-deficient diets [10, 45], based on increased oxidative stress and similar courses of disease progress between alcoholic and nonalcoholic fatty liver diseases [9].

4. Mitochondrial Dysfunction and Fatty Liver Disease Studied with Redox Proteomics Approaches

It would be ideal if the activity change of each oxidatively modified mitochondrial protein can be measured to accurately assess the degree and functional implications of mitochondrial dysfunction in different pathological conditions or before and after exposure to a potentially toxic agent including alcohol or other abused substances such as MDMA and nicotine. However, this task may be impractical due to a relatively small yield of mitochondrial proteins from whole tissue extracts and the requirement for a large amount of mitochondrial proteins for direct activity measurement. As alternative approaches, other methods including global gene expression DNA microarrays and proteomics analyses have been used to indirectly assess the relative degree of mitochondrial dysfunction [68, 93]. Although DNA microarrays allow global analysis of gene expression changes in disease states versus presumably normal control conditions, the results do not always accurately reflect the changes in the final protein amounts or activities of (mitochondrial) proteins [68, 94, 95]. Therefore, a few proteomics methods with or without gel-based tools have recently been developed to quantitatively evaluate the changes in the expressed levels of many proteins in two different specimens (e.g., disease states and apparently normal controls). The recent methods include fluorescence 2D difference in gel electrophoresis (2D DIGE) [96], cleavable isotope-coded affinity tag (clCAT) [97], isobaric tags for relative and absolute quantitation (iTRAQ) [98], multidimensional protein identification technology (MudPIT) [99], and so forth. These global proteomics methods can also be used to investigate the quantitative changes in mitochondrial proteins. In addition, a conventional proteomics approach consisting of comparative 2D gel analysis was successfully used for analyzing the protein changes in the whole tissue extracts [83, 100] or the enriched mitochondrial fractions from alcohol-exposed rats compared to corresponding controls [59]. However, despite the advantages and merits, all these global proteomics approaches may not necessarily provide valuable information about functional changes of the target proteins, since the activities of many (mitochondrial) proteins can be suppressed without significant quantitative changes of their contents, as demonstrated with ALDH2 [67, 70, 87]. These results rather suggest that the functions/activities of many (mitochondrial) proteins could be altered through posttranslational modifications such as oxidation of many amino acids including Cys residues, nitration of Tyr residues, phosphorylation of Ser, Thr and Tyr residues, acetylation of Lys residues, glycosylation of Asn residues, and adduct formation with 4-HNE, or reactive drug metabolites [65–67, 77–79, 86, 101–103]. Instead of studying covalent modifications of various amino acid residues (e.g., Cys, Trp, His, Met, Pro, Tyr, and Lys) that can be differently modified [55], we and other scientists focused on targeted proteomics approaches aiming for oxidatively modified Cys residues of many proteins that can be purified by affinity matrix, displayed on 2D PAGE gels, stained with silver, and identified by mass-spectral analysis. Identification of the oxidatively modified proteins detected with the Cys-targeted redox proteomics approach and a literature search for active site Cys residues of each oxidized protein allow us to predict functional changes (e.g., potential inhibition) of the oxidized proteins/enzymes even in the absence of any changes in protein content.

In order to study oxidative inactivation of many mitochondrial proteins responsible for causing mitochondrial dysfunction, a few redox proteomics approaches have been used to identify oxidized Cys residue(s) of many proteins by using ICAT [97], biotin-labeled iodoacetamide (BIAM) [104], 4-iodobutytriphenyl-phosphonium [87], or biotin-N-maleimide (biotin-NM) [105], being used as a major sulphydryl-detecting agent in each approach. Although each detection method has its own merit, our approach using biotin-NM as a specific probe for oxidized Cys residues revealed a positive correlation between the levels of oxidative stress in pathological conditions and the number of oxidized proteins [105]. Therefore, we believe that the redox proteomics method using biotin-NM as a sensitive probe for detecting oxidized Cys residues may have a significant advantage over the other redox proteomics methods, where the number of oxidized proteins could be inversely correlated with the increased oxidative stress and oxidized Cys residues do not efficiently react with iodoacetamide-based sulphydryl reagents BIAM and ICAT [87, 97, 104]. The specific procedures, advantages, limitations, and alternative approaches of our method and its comparison with other redox proteomics methods have been recently described in detail [106]. Excellent review articles on the theories, benefits, and limitations of various redox proteomics approaches from other laboratories are also available [107–112].

To avoid redundancy with some of the previous reviews [106–112], we briefly describe the procedure of our simple...
redox proteomics method as outlined in Figure 3. Many sulfhydryl groups of various proteins can be oxidatively modified (e.g., sulfenic acid, disulfide, sulfonic acid, sulfonic acid, and mixed disulfides including S-nitrosylation) under increased nitroxidative states. The remaining free Cys thiols of various proteins are initially reacted with N-ethylmaleimide (NEM), which irreversibly blocks the free thiols. After removing excess NEM by the first gel filtration step, the oxidized Cys residues including mixed disulfides are reduced to free Cys thiols with DTT. The newly reduced free Cys thiols are then switched with biotin-NM. After removing excess biotin-NM with the second gel filtration step, biotin-labeled oxidized proteins are detected by immunoblot analysis or affinity-purified with streptavidin-agarose beads for further characterizations. After washing the nonspecifically bound proteins, agarose-bound biotin-NM-labeled oxidized proteins are dissolved and analyzed by 1-D PAGE for detection with anti-biotin monoclonal antibody or 2D PAGE for protein display followed by identification by mass spectrometric analysis. By using a mild reducing agent ascorbate or GSH [113, 114] instead of DTT in the reduction step of NEM-modified proteins, we can specifically detect proteins with mixed disulfides (e.g., S-cysteinyl, S-glutathionyl, and S-succinyl), although the ascorbate-mediated biotin-switch method can produce false-positive artifacts [115, 116].

In fact, we used this redox proteomics approach to identify many oxidized mitochondrial proteins in ethanol-exposed human hepatoma E47-HepG2 cells with stably transfected human CYP2E1, which can produce ROS during ethanol metabolism [38, 39]. The number of oxidized proteins positively correlated with the ethanol concentration and ethanol exposure time as well as the presence of CYP2E1.
modified and some of their activities we that measured were inhibited. Temporal analyses of oxidatively modified proteins and liver histology indicated that mitochondrial dysfunction takes place long before appearance of full-blown liver damage including necroinflammation [70]. Based on these results, oxidative modification and inactivation of many mitochondrial proteins cause mitochondrial dysfunction, which then contributes to tissue injury observed at later time points. Furthermore, we expect that this redox proteomics approach can be successfully used to identify and study functional alterations of oxidatively modified proteins in mitochondrial dysfunction and tissue injury in various organs of human disease specimens.

Although these redox proteomics approaches can be used as surrogate methods to estimate the degree of mitochondrial dysfunction, they do have a few limitations. For instance, we believe that the actual number of oxidized proteins could be much greater than what we observed in our studies because of relatively poor sensitivities of gel-based redox-proteomics methods in detecting proteins expressed in low quantities. In fact, our systematic analysis using the Cys-targeted biotin-switch method was unable to detect oxidative modifications of DNA repair enzymes such as O6-methylguanine-DNA-methyltransferase, although this enzyme contains Cys in its active site and can be inactivated through S-nitrosylation [117]. By the same token, we also expect that some key enzymes involved in the cell metabolism/signaling pathways like mitochondrial Sirt3 [118–120] or certain transcription factors that contain critically important Cys residues could not be detected by the redox proteomics approaches although they could be oxidatively modified and thus inactivated by increased oxidative/nitrative stress under pathological conditions. In addition, some oxidized or nitrated proteins could be rapidly degraded through ubiquitin-dependent and -independent proteolysis [55,121–124] and thus could not be detected by the current redox proteomics methods.

We believe that these limitations associated with various redox proteomics approaches can be overcome by functional analysis (including enzyme activity measurement) supplemented with immunoprecipitation of a target protein, albeit a low level of expression, followed by immunoblot analysis with anti-Cys-S-NO, anti-glutathione, and anti-3-nitroTyr antibody for detecting S-nitrosylation, S-glutathionylation, and nitration, respectively. A few examples of other critical proteins, that were expressed in small quantities and not detected by the systematic redox proteomics analyses but reported to be suppressed through oxidative modifications, were recently discussed [106]. It is of interest whether other critical mitochondrial proteins expressed in small quantities (e.g., sirtuin 3) can be inactivated through oxidative modifications, thus directly contributing to mitochondrial dysfunction with imbalanced energy supply [118], intolerance to cold exposure with decreased fat oxidation during fasting [119], and decreased mitochondrial complex activities [120], as observed in mice deficient of mitochondrial sirtuin 3 gene. A recent report revealed that Cys280, a critical zinc binding residue, of Sirt3 is modified by 4-HNE, resulting in its allosteric inactivation [61]. It would also be of interest to study the potential mechanisms of oxidative inactivation or degradation of some transcription factors such as NFkB as observed in alcohol-exposed genetically obese mice [125] and PPARα, a key regulator of the enzymes involved in the fat metabolism [126] and shown to be decreased in alcohol-fed mice [127], in mice with nonalcoholic steatohepatitis [128], or in acetaminophen-mediated acute liver damage [129]. Finally, the study of ER-associated drug metabolizing proteins such as cytochromes P450, that have Cys residues at their catalytic sites, may provide important insights in uncoupling of the catalytic cycle during adverse drug reactions [130].

Another limitation of the redox proteomics could be reasoned that Cys residues of many proteins can undergo various types of covalent modifications such as conjugation with carbonyl compounds such as 4-HNE and MDA elevated during lipid peroxidation under oxidative stress [54,90,131] or reactive metabolites of acetaminophen, produced during the metabolism of potentially toxic compounds [77–79,124,129]. In fact, the number of oxidatively modified proteins in acetaminophen-exposed liver tissues appears relatively small ([132], and Abdelmegeed et al., unpublished observation) despite increased nitrooxidative stress [124]. These data likely reflect the fact that oxidation of Cys residues in many proteins in acetaminophen-exposed tissues could be suppressed because of their prior interactions with the reactive metabolite N-acetyl-p-benzoquinone imine and thus cannot be detected by redox proteomics approaches. However, these types of irreversible adduct formations of critical Cys residues of target proteins can be evaluated by the recovery of the functional activities after incubation with a strong reducing agent such as DTT. If the activities are restored by DTT, protein Cys residues could be modified through formation of reversible sulfenic acids or disulfides including mixed disulfides. If the activities are not recovered, Cys residues are likely modified through irreversible adducts formation [54,90,133] or hyperoxidation of Cys residues to sulfenic (~SOOH) and sulfonic (~SOOHOH) acids [117], and references herein). The possibility of these types of irreversible modification can be further confirmed by immunoprecipitation of the target protein followed by immunoblot analysis with anti-4-HNE or anti-acetaminophen antibody.

5. Applications of Redox Proteomics

Approaches to Detect Oxidized Proteins in Other Subcellular Organelles, Many Other Tissues, and Different Disease States

We have thus far described oxidative modifications of mitochondrial proteins and their functional consequences in experimental animal models of fatty liver disease. However, it is quite logical to predict that proteins located in other subcellular organelles (e.g., cytoplasm, ER, and nuclear fractions) can also be oxidatively modified and thus contribute to tissue injury. For instance, oxidative inactivation of ER-resident chaperone proteins (e.g., protein disulfide isomerase and other heat shock proteins) can cause misfolding or unfolding of their client proteins, resulting in the unfolded protein response and ER stress. Oxidative modifications and potential inactivation of nuclear proteins...
such as DNA repair enzymes including O\(^6\)-methylguanine-DNA-methyltransferase [117] or Ogg1 [56] could explain the increased levels of oxidatively modified DNA after exposure to potentially toxic compounds or under pathological conditions.

To understand the mechanism of ER stress and its pathological role, we also applied the simple biotin-switch redox proteomics method to systematically characterize oxidatively modified hepatic proteins in cytoplasm and ER from experimental animals of alcoholic and nonalcoholic fatty liver disease [134–136]. Our redox proteomics data showed that many ER-located chaperone proteins including protein disulfide isomerase, heat shock proteins, and other antioxidant enzymes including cytosolic SOD (SOD1) and peroxiredoxin are oxidized and inactivated [134, 135]. Consistent with these results, we observed increased unfolded protein responses in alcohol-exposed E47-HepG2 hepatoma cells and experimental animals (unpublished observations). It is also possible that these proteins can be inhibited through adduct formation with MDA or 4-HNE, as recently reported [133]. All these results suggest that increased ER stress, possibly originated from mitochondrial dysfunction [95] or uncoupled cytochrome P450 catalytic cycle [130], may also contribute to tissue damage.

Under specific pathological conditions or disease states, certain selected tissues are negatively affected. For instance, brain tissues are selectively distressed in neurodegenerative disorders [50] or after exposure to neurotoxic agents, while heart and blood vessels can be compromised in cardiovascular disorders. It is known that nitrooxidative stress is a common factor in these pathological conditions in various tissues (Figure 1). However, it is poorly understood which proteins are oxidatively modified under different disease states. By analyzing oxidatively modified proteins in different tissues, we can also predict functional alterations of each target protein. In addition, it is of interest whether similar sets of mitochondrial proteins are oxidatively modified in different organs/tissues (e.g., liver versus other extrahepatic tissues such as brain, heart, lung, kidney, pancreas, and intestine) or different species (e.g., rodents versus humans) when analyzed by the redox proteomics approach. Our unpublished preliminary results indicate that the overall patterns of oxidized proteins in MDMA-exposed brain tissues are similar to those of the MDMA-exposed liver tissues, except for the liver-specific proteins including the enzymes involved in the mitochondrial fat oxidation pathway. By comparing the patterns of oxidative protein modifications in different tissues and species, we can estimate the role of specific proteins in mitochondrial dysfunction and disease progression of each organ or disease state.

6. Potential Translational Applications of Redox Proteomics Approaches to Evaluate Beneficial Agents to Prevent or Treat Mitochondrial Dysfunction

Once we understand the mechanism of mitochondrial dysfunction and ER stress, contributing to tissue injury, it is desirable to develop an effective strategy of prevention or therapy against mitochondrial dysfunction and organ damage based on our knowledge. We believe that the redox-based proteomics method can be used in translational research by evaluating the effectiveness or progress of treatment with a certain beneficial agent (e.g., antioxidants or cell protective agents from natural and synthetic origins). This task can be achieved by monitoring the levels of oxidatively modified mitochondrial proteins in the biological specimens before and after treatment with a beneficial agent. For instance, we have recently demonstrated a beneficial effect of a diet containing polyunsaturated fatty acids (PUFA) with physiological levels of arachidonic and docosahexaenoic acids on effectively preventing protein oxidation, mitochondrial dysfunction, and ultimately alcoholic fatty liver [137]. These results observed in rats are consistent with the beneficial effects of PUFA diets against alcoholic fatty liver in monkeys [138] and nonalcoholic fatty liver in rats fed a choline-deficient high fat diet [139]. Our results also provide the underlying mechanisms by which physiologically relevant levels of PUFA exert beneficial effects against alcoholic fatty liver in both rats [137] and monkeys [138].

As shown in Figure 4, the number and levels of oxidatively modified mitochondrial proteins were increased in alcohol-fed control rats (Base ethanol) compared to pair-fed control rats (Base control). Our results [137] showed that increased production of hydrogen peroxide and peroxynitrite in alcohol-exposed rats (Base ethanol) compared to pair-fed control group (Base control). These results are consistent with elevated levels of CYP2E1 and iNOS in ethanol-fed rats. Immunoblot analyses of oxidized proteins from each group revealed the presence of oxidatively modified thioldase and \(\alpha\)-ATP synthase only in the Base-ethanol group. However, the increased levels of oxidized proteins in the Base-ethanol group were markedly decreased in rats fed the same amounts of alcohol in the presence of PUFA (PUFA-ethanol). Addition of PUFA to ethanol-fed rats (PUFA-ethanol) improved histological data (i.e., disappearance of fat vacuoles) with the absence of the oxidized protein bands of both thioldase and \(\alpha\)-ATP synthase detected only in the Base-ethanol group. Furthermore, the respective activities of thioldase, ATP synthase, and ALDH2, all suppressed in the Base-ethanol group, were restored in the PUFA-ethanol group. Further mechanistic studies revealed that the PUFA diet significantly prevented activation/induction of CYP2E1 and iNOS, which produce ROS and RNS, respectively, observed in alcohol-exposed tissues (Base ethanol). Consequently, the elevated levels of a potently toxic peroxynitrite, which can \(\cdot\)nitrosylate Cys residues and/or nitrate Tyr residues of various proteins [48], were significantly decreased in the PUFA-ethanol group compared to those in alcohol-fed control rats (Base ethanol).

During our mechanistic study on I/R-related mitochondrial dysfunction, we were also able to evaluate the beneficial effect of a peroxynitrite scavenger metalloporphyrin MnTMPyP against mitochondrial dysfunction and acute hepatic I/R injury [70]. MnTMPyP pretreatment markedly suppressed the I/R-related elevation of serum transaminase levels, histological damage, iNOS expression, and oxidative modifications of key mitochondrial proteins assessed.
by comparative 2D gel analysis for each sample. These changes were further supported by the activity measurements of mitochondrial ALDH2, thiolase, and ATP synthase as well as histopathological evaluation. These studies provide supporting evidence for a translational research application of the redox proteomics approach against mitochondrial dysfunction and organ damage in numerous disease states. We expect that beneficial effects of many natural antioxidant agents such as polyenophysphatidylcholine [140, 141], S-adenosylmethionine [142], resveratrol [143], curcumin [144, 145], and silymarin [144, 145] or various synthetic agents such as vitamin E analogs and carvedilol [146] against mitochondrial dysfunction and oxidative tissue injury could be demonstrated by using the redox-based proteomics approaches. Furthermore, the redox proteomics approach may also be used in finding potential biomarkers of disease states in other extrahepatic tissues including brain, heart, lung, and kidney from experimental models as well as human tissue specimens.

**Abbreviations**

ALDH2: Mitochondrial low-Km aldehyde dehydrogenase 2  
BIAM: Biotin-conjugated iodoacetamide  
Biotin-NM: Biotin-N-maleimide  
Complex I: NADH-dependent ubiquinone oxidoreductase  
Complex III: Cytochrome c reductase  
Complex IV: Cytochrome c oxidase  
CYP2E1: Ethanol-inducible cytochrome P450 2E1 isozyme  
DIGE: Difference in gel electrophoresis  
ER: Endoplasmic reticulum  
ETC: Electron transport chain  
4-HNE: 4-Hydroxynonenal  
iNOS: Inducible nitric oxide synthase  
I/R: Ischemia-reperfusion  
MDA: Malondialdehyde
MDMA: 3,4-methylenedioxymethamphetamine
NEM: N-ethylmaleimide
NO: Nitric oxide
PUFA: Polyunsaturated fatty acids
RNS: Reactive nitrogen species
ROS: Reactive oxygen species
S-NO-Cys: S-nitrosylated Cys
SOD: Superoxide dismutase
Thiolase: 3-Ketoacyl-CoA thiolase.

Acknowledgments
This research was supported by the Intramural Program Fund at the National Institute on Alcohol Abuse and Alcoholism. Part of this research was also supported by a Grant for the Chronic Liver Disease Project (to B. J. Song) from the Center for Biological Modulators in the Republic of Korea. The authors thank Dr. Klaus Gawrisch for his support. They are also grateful to Mrs. Timothy D. Veenstra, Brian L. Hood, Thomas P. Conrads, Li-Rong Yu, and Xiaoying Ye at the Laboratory of Proteomics and Analytical Technologies, Advanced Technology Program, SAIC-Frederick, Inc., for determining the protein sequences of oxidatively modified mitochondrial proteins in our studies. The authors do not have any conflict of interest.

References
[1] S. Soboll, "Regulation of energy metabolism in liver," *Journal of Bioenergetics and Biomembranes*, vol. 27, no. 6, pp. 571–582, 1995.
[2] B. Fromenty and D. Pessayre, "Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity," *Pharmacology and Therapeutics*, vol. 67, no. 1, pp. 101–154, 1995.
[3] P. Vandenabeele, L. Galluzzi, T. Vanden Berghe, and G. Kroemer, "Molecular mechanisms of necroptosis: an ordered cellular explosion," *Nature Reviews Molecular Cell Biology*, vol. 11, no. 10, pp. 700–714, 2010.
[4] C. S. Lieber, "Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis," *Alcohol*, vol. 34, no. 1, pp. 9–19, 2004.
[5] B. Gao and R. Bataller, "Alcoholic liver disease: pathogenesis and new therapeutic targets," *Gastroenterology*, vol. 141, no. 5, pp. 1572–1585, 2011.
[6] V. R. Freedy, V. B. Patel, H. J. F. Why, J. M. Corbett, M. J. Dunn, and P. J. Richardson, "Alcohol and the heart: biochemical alterations," *Cardiovascular Research*, vol. 31, no. 1, pp. 139–147, 1996.
[7] C. Harper, "The neuropathology of alcohol-related brain damage," *Alcohol and Alcoholism*, vol. 44, no. 2, pp. 136–140, 2009.
[8] A. Vonlaufen, J. S. Wilson, R. C. Pirola, and M. V. Apte, "Role of alcohol metabolism in chronic pancreatitis," *Alcohol Research and Health*, vol. 30, no. 1, pp. 48–54, 2007.
[9] A. M. Diehl, Z. Goodman, and K. G. Ishak, "Alcoholic liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury," *Gastroenterology*, vol. 95, no. 4, pp. 1056–1062, 1988.
[10] C. L. Powell, O. Kosyk, B. U. Bradford et al., "Temporal correlation of pathology and DNA damage with gene expression in a choline-deficient model of rat liver injury," *Hepatology*, vol. 42, no. 5, pp. 1137–1147, 2005.
[11] K. Otani, M. Korenaga, M. R. Beard et al., "Hepatitis C virus core protein, cytochrome P450 2E1, and alcohol produce combined mitochondrial injury and cytotoxicity in hepatoma cells," *Gastroenterology*, vol. 128, no. 1, pp. 96–107, 2005.
[12] K. Begriche, A. Igoudlij, D. Pessayre, and B. Fromenty, "Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it," *Mitochondrion*, vol. 6, no. 1, pp. 1–38, 2006.
[13] G. Kunos and D. Osei-Hyiaman, "Endocannabinoids and liver disease. IV. Endocannabinoid involvement in obesity and hepatic steatosis," *American Journal of Physiology*, vol. 294, no. 5, pp. G1101–G1104, 2008.
[14] A. R. Sudheer, S. Muthukumaran, N. Devipriya, H. Devaraj, and V. P. Menon, "Influence of ferulic acid on nicotine-induced lipid peroxidation, DNA damage and inflammation in experimental rats as compared to N-acetylcysteine," *Toxicology*, vol. 243, no. 3, pp. 317–329, 2008.
[15] K. H. Moon, V. V. Upreti, L. R. Yu et al., "Mechanism of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-mediated mitochondrial dysfunction in rat liver," *Proteomics*, vol. 8, no. 18, pp. 3906–3918, 2008.
[16] D. Cerretani, I. Riezzo, A. Fiaschi et al., "Cardiac oxidative stress determination and myocardial morphology after a single ecstasy (MDMA) administration in a rat model," *International Journal of Legal Medicine*, vol. 122, no. 6, pp. 461–469, 2008.
[17] B. J. Song, K. H. Moon, V. V. Upreti, N. D. Eddington, and I. J. Lee, "Mechanisms of mdma (ecstasy)-induced oxidative stress, mitochondrial dysfunction, and organ damage," *Current Pharmaceutical Biotechnology*, vol. II, no. 5, pp. 434–443, 2010.
[18] M. Carvalho, H. Pontes, F. Remião, M. L. Bastos, and F. Carvalho, "Mechanisms underlying the hepatotoxic effects of ecstasy," *Current Pharmaceutical Biotechnology*, vol. II, no. 5, pp. 476–495, 2010.
[19] E. Turillazzi, I. Riezzo, M. Neri, S. Bello, and V. Fineschi, "MDMA toxicity and pathological consequences: a review about experimental data and autopsy findings," *Current Pharmaceutical Biotechnology*, vol. II, no. 5, pp. 500–509, 2010.
[20] B. Fromenty and D. Pessayre, "Impaired mitochondrial function in microvesicular steatosis: effects of drugs, ethanol, hormones and cytokines," *Journal of Hepatology*, vol. 26, no. 2, pp. 43–53, 1997.
[21] Y. Wang, H. K. Seitz, and X. D. Wang, "Moderate alcohol consumption aggravates high-fat diet induced steatohepatitis in rats," *Alcoholism*, vol. 34, no. 3, pp. 567–573, 2010.
[22] C. P. Day, R. Bashir, O. F. W. James et al., "Investigation of the role of polymorphisms at the alcohol and aldehyde dehydrogenase loci in genetic predisposition to alcohol-related end-organ damage," *Hepatology*, vol. 14, no. 5, pp. 798–801, 1991.
[23] A. Yokoyama, T. Muramatsu, T. Ohmori et al., "Alcohol-related cancers and aldehyde dehydrogenase-2 in Japanese alcoholics," *Carcinogenesis*, vol. 19, no. 8, pp. 1383–1387, 1998.
[24] M. Muto, Y. Hitomi, A. Ohtsu, S. Ebihara, S. Yoshida, and H. Esumi, "Association of aldehyde dehydrogenase 2 gene polymorphism with multiple oesophageal dysplasia in head and neck cancer patients," *Gut*, vol. 47, no. 2, pp. 256–261, 2000.
[25] P. J. Brooks, M. A. Enoch, D. Goldman, T. K. Li, and A. Yokoyama, "The alcohol flushing response: an unrecognized risk factor for esophageal cancer from alcohol consumption," *PLoS Medicine*, vol. 6, no. 3, p. e50, 2009.
[26] J. B. Hoek, A. Cahill, and J. G. Pastorino, "Alcohol and mitochondria: a dysfunctional relationship," Gastroenterology, vol. 122, no. 7, pp. 2049–2063, 2002.

[27] D. C. Wallace, "A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine," Annual Review of Genetics, vol. 39, pp. 359–407, 2005.

[28] M. T. Lin and M. F. Beal, "Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases," Nature, vol. 443, no. 7113, pp. 787–795, 2006.

[29] K. B. Wallace, "Mitochondrial off targets of drug therapy," Trends in Pharmacological Sciences, vol. 12, no. 3, pp. 113–115, 2007.

[30] K. B. Wallace, "Mitochondrial off targets of drug therapy," Trends in Pharmacological Sciences, vol. 29, no. 7, pp. 361–366, 2008.

[31] D. Chandra and K. K. Singh, "Genetic insights into OXPHOS defect and its role in cancer," Biochimica et Biophysica Acta, vol. 1807, no. 6, pp. 620–625, 2011.

[32] A. Boveris and B. Chance, "The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen," Biochemical Journal, vol. 134, no. 3, pp. 707–716, 1973.

[33] R. B. Hamanaka and N. S. Chandel, "Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes," Trends in Biochemical Sciences, vol. 35, no. 9, pp. 505–513, 2010.

[34] S. M. Bailey, E. C. Pietsch, and C. C. Cunningham, "Ethanol stimulates the production of reactive oxygen species at mitochondrial complexes I and III," Free Radical Biology and Medicine, vol. 27, no. 7-8, pp. 891–900, 1999.

[35] J. C. Fernández- Checa, N. Kaplowitz, C. García-Ruiz, and A. Colell, "Mitochondrial glutathione: importance and transport," Seminars in Liver Disease, vol. 18, no. 4, pp. 389–401, 1998.

[36] S. H. Caldwell, L. A. R. de Freitas, S. H. Park et al., "Intramitochondrial crystalline inclusions in nonalcoholic steatohepatitis," Hepatology, vol. 49, no. 6, pp. 1888–1895, 2009.

[37] S. Campello and L. Scorrano, "Mitochondrial shape changes: orchestrating cell pathophysiology," EMBO Reports, vol. 11, no. 9, pp. 678–684, 2010.

[38] A. A. Caro and A. I. Cederbaum, "Oxidative stress, toxicity, and pharmacology of CYP2E1," Annual Review of Pharmacology and Toxicology, vol. 44, pp. 27–42, 2004.

[39] V. Purohit, B. Gao, and B. J. Song, "Molecular mechanisms of alcoholic fatty liver," Alcoholism, vol. 33, no. 2, pp. 191–205, 2009.

[40] J. I. Cohen, X. Chen, and L. E. Nagy, "Redox signaling and the innate immune system in alcoholic liver disease," Antioxidants and Redox Signaling, vol. 15, no. 2, pp. 523–534, 2011.

[41] S. E. McKim, E. Gábele, F. Isayama et al., "Inducible nitric oxide synthase is required in alcohol-induced liver injury: studies with knockout mice," Gastroenterology, vol. 125, no. 6, pp. 1834–1844, 2003.

[42] A. Venkatraman, S. Shiva, A. Wigley et al., "The role of iNOS in alcohol-dependent hepatotoxicity and mitochondrial dysfunction in mice," Hepatology, vol. 40, no. 3, pp. 565–573, 2004.

[43] V. Purohit, R. Rapaka, O. S. Kwon, and B. J. Song, "Role of alcohol and tobacco exposure in the development of hepatocellular carcinoma," Life Sciences, vol. 92, no. 1, pp. 3–9, 2013.

[44] S. Bansal, C. P. Liu, N. B. V. Sepuri et al., "Mitochondria-targeted cytochrome P450 2E1 induces oxidative damage and augments alcohol-mediated oxidative stress," Journal of Biological Chemistry, vol. 285, no. 32, pp. 24609–24619, 2010.

[45] I. A. Leclercq, G. C. Farrell, J. Field, D. R. Bell, F. J. Gonzalez, and G. R. Robertson, "CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis," Journal of Clinical Investigation, vol. 105, no. 8, pp. 1067–1075, 2000.

[46] P. Pacher, J. S. Beckman, and L. Liaudet, "Nitric oxide and peroxynitrite in health and disease," Physiological Reviews, vol. 87, no. 1, pp. 315–424, 2007.

[47] S. Schildknecht, R. Pape, N. Müller et al., "Neuroprotection by minocycline caused by direct and specific scavenging of peroxynitrite," Journal of Biological Chemistry, vol. 286, no. 7, pp. 4991–5002, 2011.

[48] R. Radi, J. S. Beckman, K. M. Bush, and B. A. Freeman, "Peroxynitrite oxidation of sulphydryls: the cytotoxic potential of superoxide and nitric oxide," Journal of Biological Chemistry, vol. 266, no. 7, pp. 4244–4250, 1991.

[49] J. R. Lancaster, "Nitrooxidative, nitrosative, and nitrative stress: kinetic predictions of reactive nitrogen species chemistry under biological conditions," Chemical Research in Toxicology, vol. 19, no. 9, pp. 1160–1174, 2006.

[50] T. Malinski, "Nitric oxide and nitroxidative stress in Alzheimer’s disease," Journal of Alzheimer’s Disease, vol. 11, no. 2, pp. 207–218, 2007.

[51] P. Calcerrada, G. Peluffo, and R. Radi, "Nitric oxide-derived oxidants with a focus on peroxynitrite: molecular targets, cellular responses and therapeutic implications," Current Pharmaceutical Design, vol. 17, no. 35, pp. 3905–3932, 2011.

[52] K. A. Broniowska and N. Hogg, "The chemical biology of S-nitrosothiols," Antioxidants & Redox Signaling, vol. 17, no. 7, pp. 969–980, 2012.

[53] I. G. Minko, I. D. Kozekov, T. M. Harris, C. J. Rizzo, S. R. Lloyd, and M. P. Stone, "Chemistry and biology of DNA containing 1,N2-deoxyguanosine adducts of the α,β-unsaturated aldehydes acrolein, crotonaldehyde, and 4-hydroxynonenal," Chemical Research in Toxicology, vol. 22, no. 5, pp. 759–778, 2009.

[54] H. Esterbauer, R. J. Schaur, and H. Zollner, "Chemistry and Biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes," Free Radical Biology and Medicine, vol. 11, no. 1, pp. 81–128, 1991.

[55] B. S. Berlett and E. R. Stadman, "Protein oxidation in aging, disease, and oxidative stress," Journal of Biological Chemistry, vol. 272, no. 33, pp. 20313–20316, 1997.

[56] J. Wan, M. A. Bae, and B. J. Song, "Aminoacrine-induced accumulation of 8-oxodeoxyguanosine through reduction of Oggi DNA repair enzyme in C6 glioma cells," Experimental and Molecular Medicine, vol. 36, no. 1, pp. 71–77, 2004.

[57] A. Mansouri, B. Fromenty, A. Berson et al., "Multiple hepatic mitochondrial DNA deletions suggest premature oxidative aging in alcoholic patients," Journal of Hepatology, vol. 27, no. 1, pp. 96–102, 1997.

[58] A. Mansouri, I. Gaou, C. De Kerqencet et al., "An alcoholic binge causes massive degradation of hepatic mitochondrial DNA in mice," Gastroenterology, vol. 117, no. 1, pp. 181–190, 1999.

[59] A. Venkatraman, A. Landar, A. J. Davis et al., "Modification of the mitochondrial proteome in response to the stress of ethanol-dependent hepatotoxicity," Journal of Biological Chemistry, vol. 279, no. 21, pp. 22092–22101, 2004.

[60] J. A. Doorn, T. D. Hurley, and D. R. Petersen, "Inhibition of human mitochondrial aldehyde dehydrogenase by 4-hydroxynon-2-enal and 4-oxonon-2-enal," Chemical Research in Toxicology, vol. 19, no. 1, pp. 102–110, 2006.
A. I. Cederbaum, C. S. Lieber, and E. Rubin, “Effects of chronic ethanol treatment on mitochondrial functions damage to coupling site I,” Archives of Biochemistry and Biophysics, vol. 165, no. 2, pp. 560–569, 1974.

J. Chen, N. C. Robinson, S. Schenker, T. A. Frosto, and G. I. Henderson, “Formation of 4-hydroxynonenal adducts with cytochrome c oxidase in rats following short-term ethanol intake,” Hepatology, vol. 29, no. 6, pp. 1792–1798, 1999.

J. Chen, D. R. Petersen, S. Schenker, and G. I. Henderson, “Formation of malondialdehyde adducts in livers of rats exposed to ethanol: role in ethanol mediated inhibition of cytochrome c oxidase,” Alcoholism, vol. 24, no. 4, pp. 544–552, 2000.

K. H. Moon, B. L. Hood, B. J. Kim et al., “Inactivation of oxidized and S-nitrosylated mitochondrial proteins in alcoholic fatty liver of rats,” Hepatology, vol. 44, no. 5, pp. 1218–1230, 2006.

H. Lu, V. Koshkin, E. M. Allister, A. V. Gyulkhandanyan, and M. B. Wheeler, “Molecular and metabolic evidence for mitochondrial defects associated with β-cell dysfunction in a mouse model of type 2 diabetes,” Diabetes, vol. 59, no. 2, pp. 448–459, 2010.

K. J. Menzies, B. H. Robinson, and D. A. Hood, “Effect of thyroid hormone on mitochondrial properties and oxidative stress in cells from patients with mtDNA defects,” American Journal of Physiology, vol. 296, no. 2, pp. C355–C362, 2009.

K. H. Moon, B. L. Hood, P. Mukhopadhyay et al., “Oxidative inactivation of key mitochondrial proteins leads to dysfunction and injury in hepatic ischemia reperfusion,” Gastroenterology, vol. 135, no. 4, pp. 1344–1357, 2008.

S. A. Marchitti, C. Brocker, D. Stagos, and V. Vasiliiou, “Non-4540 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily,” Expert Opinion on Drug Metabolism and Toxicology, vol. 4, no. 6, pp. 697–720, 2008.

W. J. Black, D. Stagos, S. A. Mareghetti et al., “Human aldehyde dehydrogenase genes: alternatively spliced transcriptional variants and their suggested nomenclature,” Pharmacogenetics and Genomics, vol. 19, no. 11, pp. 893–902, 2009.

D. P. Hartley, J. A. Ruth, and D. R. Petersen, “The hepatocellular metabolism of 4-hydroxynonenal by alcohol dehydrogenase, aldehyde dehydrogenase, and glutathione S-transferase,” Archives of Biochemistry and Biophysics, vol. 316, no. 1, pp. 197–205, 1995.

T. C. Murphy, V. Amarnath, and M. J. Picklo, “Mitochondrial oxidation of 4-hydroxy-2-nonenal in rat cerebral cortex,” Journal of Neurochemistry, vol. 84, no. 6, pp. 1313–1321, 2003.

A. A. Klyosov, L. G. Rashkovetsky, M. K. Tahir, and W. M. Keung, “Possible role of liver cytosolic and mitochondrial aldehyde dehydrogenases in acetate metabolism,” Biochemistry, vol. 35, no. 14, pp. 4445–4456, 1996.

M. A. Abdelmegeed, S. H. Yoo, L. E. Henderson, F. J. Gonzalez, K. J. Woodcroft, and B. J. Song, “PPARα expression protects male mice from high fat-induced nonalcoholic fatty liver,” Journal of Nutrition, vol. 141, no. 4, pp. 603–610, 2011.

D. Y. Mitchell and D. R. Petersen, “Inhibition of rat liver aldehyde dehydrogenases by acrolein,” Drug Metabolism and Disposition, vol. 16, no. 1, pp. 37–42, 1988.

J. S. Landin, S. D. Cohen, and E. A. Khairallah, “Identification of a 54-kDa mitochondrial acetylcholinesterase-binding protein as aldehyde dehydrogenase,” Toxicology and Applied Pharmacology, vol. 141, no. 1, pp. 299–307, 1996.

J. J. Lipsky, M. L. Shen, and S. Naylor, “Overview—in vitro inhibition of aldehyde dehydrogenase by disulfiram and metabolites,” Chemico-Biological Interactions, vol. 130–132, pp. 81–91, 2001.

C.-H. Chen, G. R. Budas, E. N. Churchill, M. H. Disatnik, T. D. Hurley, and D. Mochly-Rosen, “Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart,” Science, vol. 321, no. 5895, pp. 1493–1495, 2008.

K. R. Palmer and W. J. Jenkins, “Aldehyde dehydrogenase in alcoholic subjects,” Hepatology, vol. 5, no. 2, pp. 260–263, 1985.

P. Banfi, C. Lanzi, F. S. Falvella, M. Gariboldi, R. A. Gambetta, and T. A. Dragani, “The daunorubicin-binding protein of Mr 54,000 is an aldehyde dehydrogenase and is down-regulated in mouse liver tumors and in tumor cell lines,” Molecular Pharmacology, vol. 46, no. 5, pp. 896–900, 1994.

K. S. Park, S. Y. Cho, H. Kim, and Y. K. Paik, “Proteomic alterations of the variants of human aldehyde dehydrogenase isozymes correlate with hepatocellular carcinoma,” International Journal of Cancer, vol. 97, no. 2, pp. 261–265, 2002.

K. H. Moon, M. A. Abdelmegeed, and B. J. Song, “Inactivation of cytosolic aldehyde dehydrogenase via S-nitrosylation in ethanol-exposed rat liver,” FEBS Letters, vol. 581, no. 21, pp. 3967–3972, 2007.

K. H. Moon, B. J. Kim, and B. J. Song, “Inhibition of mitochondrial aldehyde dehydrogenase by nitric oxide-mediated S-nitrosylation,” FEBS Letters, vol. 579, no. 27, pp. 6115–6120, 2005.

B. J. Song, M. A. Abdelmegeed, S.-H. Yoo et al., “Post-translational modifications of mitochondrial aldehyde dehydrogenase and biomedical implications,” Journal of Proteomics, vol. 74, no. 12, pp. 2691–2702, 2011.

A. Venkatraman, A. Landar, A. J. Davis et al., “Oxidative modification of hepatic mitochondria protein thiols: effect of chronic alcohol consumption,” American Journal of Physiology, vol. 286, no. 4, pp. G521–G527, 2004.

C. Brocker, N. Lassen, T. Ester et al., “Aldehyde dehydrogenase 7A1 (ALDH7A1) is a novel enzyme involved in cellular defense against hyperosmotic stress,” Journal of Biological Chemistry, vol. 285, no. 24, pp. 18452–18463, 2010.

K. H. Moon, Y. M. Lee, and B. J. Song, “Inhibition of hepatic mitochondrial aldehyde dehydrogenase by carbon tetrachloride through JNK-mediated phosphorylation,” Free Radical Biology and Medicine, vol. 48, no. 3, pp. 391–398, 2010.

B. P. Sampey, S. Korourian, M. J. Ronis, T. M. Badger, and D. R. Petersen, “Immunohistochemical characterization of hepatic malondialdehyde and 4-hydroxynonenal modified proteins during early stages of ethanol-induced liver injury,” Alcoholism, vol. 27, no. 6, pp. 1015–1022, 2003.

V. V. Upreti, N. D. Eddington, K. H. Moon, B. J. Song, and I. J. Lee, “Drug interaction between ethanol and 3,4-methylenedioxyamphetamine (‘ecstasy’),” Toxicology Letters, vol. 188, no. 2, pp. 167–172, 2009.

M. A. Abdelmegeed, K. H. Moon, J. P. Hardwick, F. J. Gonzalez, and B. J. Song, “Role of peroxisome proliferator-activated receptor-α in fasting-mediated oxidative stress,” Free Radical Biology and Medicine, vol. 47, no. 6, pp. 767–778, 2009.
[93] D. S. Johnston, Y. A. Su, and S. Alesci, “Mitochondrial gene profiling: translational perspectives,” Pharmacogenomics, vol. 10, no. 10, pp. 1645–1655, 2009.

[94] S. P. Gygi, Y. Rochon, B. R. Franz, and R. Aebersold, “Correlation between protein and mRNA abundance in yeast,” Molecular and Cellular Biology, vol. 19, no. 3, pp. 1720–1730, 1999.

[95] A. V. Kozlov, J. C. Duvinage, I. Miller et al., “Endotoxin causes functional endoplasmic reticulum failure, possibly mediated by mitochondria,” Biochimica et Biophysica Acta, vol. 1792, no. 6, pp. 521–530, 2009.

[96] R. P. Tonge, J. Shaw, B. Middleton et al., “Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology,” Proteomics, vol. 1, no. 3, pp. 377–396, 2001.

[97] M. Sethuraman, M. E. McCombs, T. Heibeck, C. E. Costellos, and R. A. Cohen, “Isotope-coded affinity tag approach to identify and quantify oxidant-sensitive protein thiols,” Molecular and Cellular Proteomics, vol. 3, no. 3, pp. 273–278, 2004.

[98] W. W. Wu, G. Wang, S. J. Baek, and R. F. Shen, “Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF,” Journal of Proteome Research, vol. 5, no. 3, pp. 651–658, 2006.

[99] M. P. Washburn, D. Wolters, and J. R. Yates, “Large-scale analysis of the yeast proteome by multidimensional protein identification technology,” Nature Biotechnology, vol. 19, no. 3, pp. 242–247, 2001.

[100] M. Ünlü, M. E. Morgan, and J. I. Minden, “Difference gel electrophoresis: a single gel method for detecting changes in protein extracts,” Electrophoresis, vol. 18, no. 11, pp. 2071–2077, 1997.

[101] B. J. Kim, S. W. Ryu, and B. J. Song, “[NK- and p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells,” Journal of Biological Chemistry, vol. 281, no. 30, pp. 21256–21265, 2006.

[102] Y. Yang, H. Cimen, M. J. Han et al., “NAD+–dependent deacetylase SIRT3 regulates mitochondrial protein synthesis by deacetylation of the ribosomal protein MRPL10,” Journal of Biological Chemistry, vol. 285, no. 10, pp. 7417–7429, 2010.

[103] Y. Hu, J. Suarez, E. Fricovsky et al., “Increased enzymatic O-GlcNAcylation of mitochondrial proteins impairs mitochondrial function in cardiac myocytes exposed to high glucose,” Journal of Biological Chemistry, vol. 284, no. 1, pp. 547–555, 2009.

[104] J. R. Kim, H. W. Yoon, K. S. Kwon, S. R. Lee, and S. G. Rhee, “Identification of proteins containing cysteine residues that are sensitive to oxidation by hydrogen peroxide at neutral pH,” Analytical Biochemistry, vol. 283, no. 2, pp. 214–221, 2000.

[105] S. K. Suh, B. L. Hood, B. J. Kim, T. P. Conrads, T. D. Veenstra, and B. J. Song, “Identification of oxidized mitochondrial proteins in alcohol-exposed human hepatoma cells and mouse liver,” Proteomics, vol. 4, no. 11, pp. 3401–3412, 2004.

[106] B. J. Song, S. K. Suh, and K. H. Moon, “A simple method to systematically study oxidatively modified proteins in biological samples and its applications,” Methods in Enzymology, vol. 473, pp. 251–264, 2010.

[107] I. Dalle-Donne, A. Scaloni, D. Giustarini et al., “Proteins as biomarkers of oxidativ/e/nitrosative stress in diseases: the contribution of redox proteomics,” Mass Spectrometry Reviews, vol. 24, no. 1, pp. 55–99, 2005.

[108] B. Derakhshan, P. C. Wille, and S. S. Gross, “Unbiased identification of cysteine S-nitrosylation sites on proteins,” Nature Protocols, vol. 2, no. 7, pp. 1685–1691, 2007.

[109] N. J. Kettenhofen, X. Wang, M. T. Gladwin, and N. Hogg, “In-gel detection of S-nitrosated proteins using fluorescence methods,” Methods in Enzymology, vol. 441, pp. 53–71, 2008.

[110] G. Chiappetta, S. Ndiaye, A. Igbaria, C. Kumar, J. Vinh, and M. B. Toledano, “Proteome screens for Cys residues oxidation: the redoxome,” Methods in Enzymology, vol. 473, pp. 199–216, 2010.

[111] K. K. Andringa and S. M. Bailey, “Detection of protein thiols in mitochondrial oxidative phosphorylation complexes and associated proteins,” Methods in Enzymology, vol. 474, pp. 83–108, 2010.

[112] E. T. Chouchani, A. M. James, I. M. Fearnley, K. S. Lilley, and M. P. Murphy, “Proteomic approaches to the characterization of protein thiol modification,” Current Opinion in Chemical Biology, vol. 15, no. 1, pp. 120–128, 2011.

[113] M. Kashiba-Iwatsuki, K. Kito, E. Kasahara et al., “Ascorbic acid and reducing agents regulate the fates and functions of S-nitrosothiols,” Journal of Biochemistry, vol. 122, no. 6, pp. 1208–1214, 1997.

[114] S. R. Jaffrey and S. H. Snyder, “The biotin switch method for the detection of S-nitrosylated proteins,” Science’s STKE, vol. 2001, no. 86, p. PL1, 2001.

[115] M. T. Gladwin, X. Wang, and N. Hogg, “Methodological vexation about thiol oxidation versus S commentary on ‘An ascorbate-dependent artifact that interferes with the interpretation of the biotin-switch assay’,” Free Radical Biology and Medicine, vol. 41, no. 4, pp. 557–561, 2006.

[116] B. Huang and C. Chen, “An ascorbate-dependent artifact that interferes with the interpretation of the biotin switch assay,” Free Radical Biology and Medicine, vol. 41, no. 4, pp. 562–567, 2006.

[117] F. Laval and D. A. Wink, “Inhibition by nitric oxide of the repair protein, O’-methylguanine-DNA-methyltransferase,” Carcinogenesis, vol. 15, no. 3, pp. 443–447, 1994.

[118] B. H. Ahn, H. S. Kim, S. Song et al., “A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 38, pp. 14447–14452, 2008.

[119] M. D. Hirschey, T. Shimazu, E. Goetzman et al., “SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation,” Nature, vol. 464, no. 7285, pp. 121–125, 2010.

[120] A. A. Kendrick, M. Choudhury, S. M. Rahman et al., “Fatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacytlation,” Biochemical Journal, vol. 433, no. 3, pp. 505–514, 2011.

[121] A. J. Gow, D. Duran, S. Malcolm, and H. Ischiropoulos, “Effects of peroxynitrite-induced protein modifications on tyrosine phosphorylation and degradation,” FEBS Letters, vol. 385, no. 1-2, pp. 63–66, 1996.

[122] R. Widmer, B. Kaiser, M. Engels, T. Jung, and T. Grune, “Hyperammonemia causes protein oxidation and enhanced proteasomal activity in response to mitochondria-mediated oxidative stress rat primary astrocytes,” Archives of Biochemistry and Biophysics, vol. 464, no. 1, pp. 1–11, 2007.

[123] C. Polge, M. Jaquinod, F. Holzer, J. Bourguignon, L. Walling, and R. Brouquisse, “Evidence for the existence in Arabidopsis thaliana of the proteasome proteolytic pathway: activation in response to cadmium,” Journal of Biological Chemistry, vol. 284, no. 51, pp. 35412–35424, 2009.

[124] M. A. Abdelmegeed, K. H. Moon, C. Chen, F. J. Gonzalez, and B. J. Song, “Role of cytochrome P450 2E1 in protein nitration and ubiquitin-mediated degradation during acetaminophen toxicity,” Biochemical Pharmacology, vol. 79, no. 1, pp. 57–66, 2010.
M. A. Robin, C. Demellier, A. Sutton et al., “Alcohol increases tumor necrosis factor \( \alpha \) and decreases nuclear factor-\( \kappa \)B to activate hepatic apoptosis in genetically obese mice,” Hepatology, vol. 42, no. 6, pp. 1280–1290, 2005.

J. P. Hardwick, D. Osei-Hyiaman, H. Wiland, M. A. Abdelmegeed, and B. J. Song, “PPAR/RXR regulation of fatty acid metabolism and fatty acid omega-hydroxylase (CYP4) isozymes: implications for prevention of lipotoxicity in fatty liver disease,” PPAR Research, vol. 2009, Article ID 952734, 2009.

M. Fischer, M. You, M. Matsumoto, and D. W. Crabb, “Peroxisome proliferator-activated receptor \( \alpha \) (PPAR\( \alpha \)) agonist treatment reverses PPAR\( \alpha \) dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice,” Journal of Biological Chemistry, vol. 278, no. 30, pp. 27997–28004, 2003.

S. Donthamsetty, V. S. Bhave, M. S. Mitra, J. R. Latendresse, and H. M. Mehendale, “Nonalcoholic steatohepatitic (NASH) mice are protected from higher hepatotoxicity of acetaminophen upon induction of PPAR\( \alpha \) with clofibrate,” Toxicology and Applied Pharmacology, vol. 230, no. 3, pp. 327–337, 2008.

C. Chen, K. W. Krausz, Y. M. Shah, J. R. Idle, and F. J. Gonzalez, “Serum metabolomics reveals reversible inhibition of fatty acid \( \beta \)-oxidation through the suppression of PPAR\( \alpha \) activation as a contributing mechanism of acetaminophen-induced hepatotoxicity,” Chemical Research in Toxicology, vol. 22, no. 4, pp. 699–707, 2009.

N. Shakunthala, “New cytochrome P450 mechanisms: implications for understanding molecular basis for drug toxicity at the level of the cytochrome,” Expert Opinion on Drug Metabolism and Toxicology, vol. 6, no. 1, pp. 1–15, 2010.

A. Català, “Lipid peroxidation of membrane phospholipids generates hydroxy-alkenals and oxidized phospholipids active in physiological and/or pathological conditions,” Chemistry and Physics of Lipids, vol. 157, no. 1, pp. 11–11, 2009.

K. K. Andringa, M. L. Bajt, H. Jaeschke, and S. M. Bailey, “Mitochondrial protein thiol modifications in acetaminophen hepatotoxicity: effect on HMG-CoA synthase,” Toxicology Letters, vol. 177, no. 3, pp. 188–197, 2008.

R. L. Smathers, J. J. Galligan, B. J. Stewart, and D. R. Petersen, “Overview of lipid peroxidation products and hepatic protein modification in alcoholic liver disease,” Chemico-Biological Interactions, vol. 192, no. 1-2, pp. 107–112, 2011.

B. J. Kim, B. L. Hood, R. A. Aragon et al., “Increased oxidation and degradation of cytosolic proteins in alcohol-exposed mouse liver and hepatoma cells,” Proteomics, vol. 6, no. 4, pp. 1250–1260, 2006.

V. V. Uperti, K. H. Moon, L. R. Yu et al., “Increased oxidative-modifications of cytosolic proteins in 3,4-methylenedioxyamphetamine (MDMA, ecstasy)-exposed rat liver,” Proteomics, vol. 11, no. 2, pp. 202–211, 2011.

M. A. Abdelmegeed, A. Banerjee, S. H. Yoo, S. H. Jang, F. J. Gonzalez, and B. J. Song, “Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis,” Journal of Hepatology, vol. 57, no. 4, pp. 860–866, 2012.

B. J. Song, K. H. Moon, N. U. Olsson, and N. Salem, “Prevention of alcoholic fatty liver and mitochondrial dysfunction in the rat by long-chain polyunsaturated fatty acids,” Journal of Hepatology, vol. 49, no. 2, pp. 262–273, 2008.

R. J. Pawlosky, B. M. Flynn, and N. Salem Jr., “The effects of low dietary levels of polyunsaturates on alcohol-induced liver disease in rhesus monkeys,” Hepatology, vol. 26, no. 6, pp. 1386–1392, 1997.

F. Takayama, K. Nakamoto, N. Totani et al., “Effects of docosahexaenoic acid in an experimental rat model of nonalcoholic steatohepatitis,” Journal of Oleo Science, vol. 59, no. 8, pp. 407–414, 2010.

H. K. Seitz, C. S. Lieber, F. Stickel, M. Salaspuro, H. P. Schlemmer, and Y. Horie, “Alcoholic liver disease: from pathophysiology to therapy,” Alcoholism, vol. 29, no. 7, pp. 1276–1281, 2005.

W. Okiyama, N. Tanaka, T. Nakajima et al., “Polyenephosphatidylcholine prevents alcoholic liver disease in PPAR\( \alpha \)-null mice through attenuation of increases in oxidative stress,” Journal of Hepatology, vol. 50, no. 6, pp. 1236–1246, 2009.

S. M. Bailey, G. Robinson, A. Pinner et al., “S-adenosyl-methionine prevents chronic alcohol-induced mitochondrial dysfunction in the rat liver,” American Journal of Physiology, vol. 291, no. 5, pp. G857–G867, 2006.

A. Kasdallah-Grissa, B. Mornagui, E. Aouani et al., “Resveratrol, a red wine polyphenol, attenuates ethanol-induced oxidative stress in rat liver,” Life Sciences, vol. 80, no. 11, pp. 1033–1039, 2007.

A. S. Darvesh, R. T. Carroll, A. Bishaye, W. J. Geldenhuyys, and C. J. Van der Schyf, “Oxidative stress and Alzheimer’s disease: dietary polyphenols as potential therapeutic agents,” Expert Review of Neurotherapeutics, vol. 10, no. 5, pp. 729–745, 2010.

H. L. Ha, H. J. Shin, M. A. Feitelson, and D. Y. Yu, “Oxidative stress and antioxidants in hepatic pathogenesis,” World Journal of Gastroenterology, vol. 16, no. 48, pp. 6035–6043, 2010.

R. M. V. Abreu, D. J. S. L. Santos, and A. J. M. Moreno, “Effects of carvedilol and its analog BM-910228 on mitochondrial function and oxidative stress,” Journal of Pharmacology and Experimental Therapeutics, vol. 295, no. 3, pp. 1022–1030, 2000.